Your browser doesn't support javascript.
loading
Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis.
Chem, Elvis Dzelamonyuy; Van Hout, Marie Claire; Hope, Vivian.
Affiliation
  • Chem ED; Public Health Institute, Liverpool John Moores University, Liverpool, UK. e.d.chem17@gmail.com.
  • Van Hout MC; Public Health Institute, Liverpool John Moores University, Liverpool, UK.
  • Hope V; Public Health Institute, Liverpool John Moores University, Liverpool, UK.
BMC Infect Dis ; 19(1): 723, 2019 Aug 16.
Article in En | MEDLINE | ID: mdl-31420021
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) in HIV endemic settings is a major threat to public health. MDR-TB is a substantial and underreported problem in Sub-Saharan Africa (SSA), with recognised cases projected to increase with advancement in diagnostic technology. There is paucity of review evidence on treatment outcomes and antiretroviral (ART) uptake among MDR-TB patients with HIV in SSA. To address this gap a review of treatment outcomes in HIV patients co-infected with MDR-TB in the SSA region was undertaken. METHODS: Three databases (Medline, Web of Science, CINHAL), Union on Lung Heath conference proceedings and grey literature were searched for publications between January 2004 and May 2018. Records were assessed for eligibility and data extracted. Random effect meta-analysis was conducted using STATA and Cochrane's review manager. RESULTS: A total of 271 publications were identified of which nine fulfilled the inclusion criteria. Data was collected from 3368 MDR-TB and HIV co-infected patients from four SSA countries; South Africa (6), Lesotho (1), Botswana (1) and Ethiopia (1). The most common outcome was cure (34.9% cured in the pooled analysis), this was followed by death (18.1% in pooled analysis). ART uptake was high, at 83% in the pooled analysis. Cure ranged from 28.6 to 54.7% among patients on ART and from 22.2 to 57.7%  among those not on ART medication. MDR-TB and HIV co-infected patients were less likely to be successfully treated than HIV negative MDR-TB patients (Risk Ratio = 0.87, 95% CI 0.97, 0.96). CONCLUSION: Treatment outcomes for MDR-TB and HIV co-infected patients do not vary widely from those reported globally. However, treatment success was lower among HIV positive MDR-TB patients compared to HIV negative MDR-TB patients. Prompt antiretroviral initiation and interventions to improve treatment adherence are necessary.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Tuberculosis, Multidrug-Resistant / Anti-HIV Agents Type of study: Etiology_studies / Prognostic_studies / Systematic_reviews Limits: Humans Country/Region as subject: Africa Language: En Journal: BMC Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2019 Type: Article

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Tuberculosis, Multidrug-Resistant / Anti-HIV Agents Type of study: Etiology_studies / Prognostic_studies / Systematic_reviews Limits: Humans Country/Region as subject: Africa Language: En Journal: BMC Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2019 Type: Article